Sign In
Buy VCNX
$0.83
-0.270 (-24.58%)
At Close: Jun 23, 2026
Vaccinex Reports 2025 Annual Financial Results
08:05pm, Wednesday, 29'th Apr 2026
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer's, Huntington
Head to Head Contrast: Evofem Biosciences (NASDAQ:EVFM) versus Vaccinex (NASDAQ:VCNX)
01:46am, Thursday, 25'th Dec 2025
Valuation and Earnings This table compares Evofem Biosciences and Vaccinex"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Ear
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. Neoadjuvant treatment with pepinemab appears to induce abu
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinema
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
05:15pm, Friday, 07'th Mar 2025
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to tre
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
08:30am, Monday, 18'th Nov 2024
Actively Exploring Partnership for Alzheimer's Development Supplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage bi
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
08:30am, Thursday, 07'th Nov 2024
Partnerships will employ Vaccinex's ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. Pepine
Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's disease Company descri
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
08:30am, Wednesday, 18'th Sep 2024
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to
ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's di
Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegen
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
06:00pm, Wednesday, 15'th May 2024
Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer's Disease in early June 2024. $8.2 million of new financing in Q1.
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
08:30am, Tuesday, 02'nd Apr 2024
Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
08:30am, Wednesday, 27'th Mar 2024
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to
